CN104800721B - A kind of pharmaceutical composition for treating factitial proctitis after irradiation for cervical cancer - Google Patents
A kind of pharmaceutical composition for treating factitial proctitis after irradiation for cervical cancer Download PDFInfo
- Publication number
- CN104800721B CN104800721B CN201510175736.7A CN201510175736A CN104800721B CN 104800721 B CN104800721 B CN 104800721B CN 201510175736 A CN201510175736 A CN 201510175736A CN 104800721 B CN104800721 B CN 104800721B
- Authority
- CN
- China
- Prior art keywords
- parts
- medicinal material
- raw materials
- traditional chinese
- chinese medicinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of pharmaceutical compositions for treating factitial proctitis after irradiation for cervical cancer, the liquid is prepared by traditional Chinese medicinal material raw materials, by weight, the traditional Chinese medicinal material raw materials include 7 15 parts of RADIX KADSURAE LONGIPEDUN LATAE, it is black lead a cow 11 20 parts, 10 25 parts of sophora flower, 6 10 parts of galanga galangal seed, 22 40 parts of chestnut shell, 6 10 parts of schizonepeta, 9 20 parts of Herba Euphorbiae Humifusae, 6 10 parts of spina gleditsiae, 11 20 parts of fevervine.The pharmaceutical composition of the present invention is curative for effect through enema treatment chronic radioactive rectitis, and safe and reliable.
Description
Technical field
The invention belongs to technical field of Chinese medicine, and in particular to factitial proctitis after a kind of enema treatment irradiation for cervical cancer
Pharmaceutical composition.
Background technology
Cervical carcinoma is most common tumor of pelvis, occupies gynecologic malignant tumor first place always in China, and radiotherapy is cervical carcinoma
Primary treatments.Chronic radioactive rectitis is a kind of common complication occurred after irradiation for cervical cancer, by acute radiation
Property rectitis delay or direct irradiation half a year after cause interstitial fibrosis, artery occlusive intimitis and cause local organization
Rectum chronic inflammation, bowel narrow, ulcer and fistula are formed caused by ischemic, can cause the serious radioactivity of permanent protracted course of disease
Damage, it brings great pain to patients, and seriously affects the life quality of patient.
At present, there is no standard treatments both at home and abroad, systemic therapy with anti-infective, hemostasis, strengthen based on the treatments such as nutrition,
Local treatment mostly with compound procaine enema fluid (procaine+gentamicin+steroid hormone) bowel lavage, there is certain treatment
Effect, but studies have found that, the enema containing steroid hormone, which is used for a long time, can cause Fu Niye gangrenous, and can also make to have blood in stool
Exacerbation of symptoms.Therefore, finding safer effective therapy is particularly important.
Invention content
In view of the deficiencies in the prior art, the purpose of the present invention is to provide radioactivity after a kind of enema treatment irradiation for cervical cancer
The pharmaceutical composition of rectitis and its application.
The object of the present invention is achieved like this：
A kind of pharmaceutical composition for treating factitial proctitis after irradiation for cervical cancer, is prepared by traditional Chinese medicinal material raw materials, pressed
Parts by weight meter, the traditional Chinese medicinal material raw materials include：7-15 parts of RADIX KADSURAE LONGIPEDUN LATAE, it is black lead a cow 11-20 parts, 10-25 parts of sophora flower, red bean
6-10 parts cool, 22-40 parts of chestnut shell, 6-10 parts of schizonepeta, 9-20 parts of Herba Euphorbiae Humifusae, 6-10 parts of spina gleditsiae, 11-20 parts of fevervine.
Preferably, as described above treatment irradiation for cervical cancer after factitial proctitis pharmaceutical composition, by weight, institute
The traditional Chinese medicinal material raw materials stated by 9-12 parts of RADIX KADSURAE LONGIPEDUN LATAE, it is black lead a cow 14-16 parts, 15-21 parts of sophora flower, 7-9 parts of galanga galangal seed, chestnut shell
14-16 parts of 28-32 parts, 7-9 parts of schizonepeta, 13-15 parts of Herba Euphorbiae Humifusae, 7-9 parts of spina gleditsiae and fevervine form.
In the most preferred embodiment of the present invention, factitial proctitis after treatment irradiation for cervical cancer as described above
Pharmaceutical composition, by weight, the traditional Chinese medicinal material raw materials by 10 parts of RADIX KADSURAE LONGIPEDUN LATAE, it is black lead a cow 15 parts, it is 18 parts of sophora flower, red
15 parts of 8 parts of cardamom, 30 parts of chestnut shell, 8 parts of schizonepeta, 14 parts of Herba Euphorbiae Humifusae, 8 parts of spina gleditsiae and fevervine compositions.
The preparation method of bowel lavage liquid of the present invention includes the following steps：It takes 7-15 parts of RADIX KADSURAE LONGIPEDUN LATAE, black lead a cow
11-20 parts, 10-25 parts of sophora flower, 6-10 parts of galanga galangal seed, 22-40 parts of chestnut shell, 6-10 parts of schizonepeta, 9-20 parts of Herba Euphorbiae Humifusae, spina gleditsiae 6-
10 parts and 11-20 parts of fevervine merge, and are ground into particle, then water is added to cover powder above-mentioned graininess medicinal material, impregnate 0.5-
1.5h is added water to cook 1-4 times, and by four layers of gauze filtration of decocting liquid, heating is concentrated into the liquid that crude drug content is 0.3-1.0g/ml,
Appropriate preservative is added in, obtains bowel lavage liquid.
It should be noted that traditional Chinese medicinal material raw materials have following source used by the pharmaceutical composition of the present invention：The southern five tastes
Sub- root selects the dry root of Magnoliacea plant schisandra chinensis Schisandra sphenanthera Rehd.et Wils..It is black
It leads a cow and selects the dry root of pinkwort gland flower silene aprica Silene adenantha Franch..Sophora flower selects legume
The drying flower and alabastrum of Chinese scholartree Sophora japonica L..Galanga galangal seed selects zingiberaceous plant Alpinia galanga Alpinia galanga
Willd. dry mature fruit.Chestnut shell selects the outer fruit of the drying of Fagaceae Chinese chestnut Castanea mollissima Bl.
Skin.Schizonepeta selects the dry aerial parts of labiate schizonepeta Schizonepeta tenuifolia Briq..Herba Euphorbiae Humifusae selects
With the drying herb of euphorbia plant humid euphorbia Euphorbia humifusa Willd..Spina gleditsiae selects legume Chinese honey locust
The drying quil of Gleditsia sinensis Lam..Fevervine selects Rubiaceae Paederia plant fevervine Paederia
The dry root of scandens (Lour.) Merr..
The present invention by chronic radioactive rectitis after herbal drug enema in treatment irradiation for cervical cancer, and with use compound Proca
Because enema fluid enema treatment compares, two groups of treatments of display are effective, but test group is in total effective rate, improvement symptom overall score side
Face is substantially better than control group.Test group does not also occur adverse events, illustrates that the pharmaceutical composition of the present invention is chronic through enema treatment
Factitial proctitis is curative for effect, and safe and reliable.
Specific embodiment
The following is specific embodiments of the present invention, and technical scheme of the present invention is done and is further described, but of the invention
Protection domain be not limited to these embodiments.It is every to be included in this hair without departing substantially from the change of present inventive concept or equivalent substitute
Within bright protection domain.
Embodiment 1
Weigh RADIX KADSURAE LONGIPEDUN LATAE 1.0kg, the black 1.5kg that leads a cow, sophora flower 1.8kg, galanga galangal seed 0.8kg, chestnut shell 3.0kg, schizonepeta
0.8kg, Herba Euphorbiae Humifusae 1.4kg, spina gleditsiae 0.8kg and fevervine 1.5kg merge, are ground into particle, then by above-mentioned graininess medicinal material
Water is added to cover powder 2cm, 1h is impregnated, adds water to cook 2 times, adds up the water of 15 times of amounts of medicinal material for the first time, 3h is decocted, takes decocting liquid, is filtered
It crosses, second of the water for adding up 12 times of amounts of medicinal material decocts 2h, takes decocting liquid merging twice, 4 layers of gauze filtration, and heating is concentrated into crude drug
Content is the liquid of 0.5g/ml, adds in 0.05% preservative, obtains bowel lavage liquid.
2 liquid medicine enema of embodiment after irradiation for cervical cancer the effect of chronic radioactive rectitis patient to studying
Cervical carcinoma chronic radioactive rectitis inpatient 42, average age (53.1 ± 9.4) year, from start radiotherapy to
There is chronic radioactive (8.9 ± 1.4) moon rectitis average time；Symptom overall score (5.90 ± 1.26) point；Wherein 29 idols
See and have blood in stool, mucosa edema, defecation is irregular, loose stools or constipation；10 common to have blood in stool, and mucous membrane is plump, proctostenosis, and defecation is stranded
Difficulty is still alleviated with drug, 3 whole bloods just, ulcer or fistula formed, proctostenosis, defecation exceptional hardship or even obstruction.It will
All patients are divided into test group and each 21 of control group using simple randomization digits table.Two groups of ages, chronic radioactive rectum
The differences such as scorching time of origin, the chronic radioactive rectitis state of an illness are not statistically significant, are comparable.
Test group is placed in using enema fluid about 200mL prepared by the embodiment of the present invention 1 in enema bag, retains fill 2 times a day
Intestines, 15 minutes every time, 2 weeks were 1 course for the treatment of.Control group uses《Occupational sanitary standard》The compound procaine bowel lavage of recommendation
Liquid, specific formula：0.25% 80,000 units of procaine 200m l+ gentamicins+‰ adrenaline 2ml of prednisone 10mg+1；Often
2 retention enemas of day, 15 minutes every time, 2 weeks were 1 course for the treatment of.Test group and control group respectively observe 1 course for the treatment of.
Curative effect determinate standard refers to《New Chinese medicine guideline of clinical investigations》About " new Chinese medicine treats the clinic of diarrhea
The criterion of the effect of research guideline " is formulated.(1) it fully recovers：Symptom disappear or mostly disappear, the reduction of symptom overall score >=
95%.(2) it is effective：Symptom is obviously improved, and 70%≤symptom overall score reduces ＜ 95%.(3) effectively：Symptom is improved,
30%≤symptom overall score reduces ＜ 70%.(4) it is invalid：Symptom is not improved or even aggravates, and symptom overall score reduces ＜
30%.Score slip=overall score after overall score-treatment before [﹙ treatments)/overall score before treating] × 100%.Total effective rate=
[﹙ recoveries from illness number of cases+effective number of cases+effective number of cases)/this group of total number of cases] × 100%.
Symptom score canonical reference《New Chinese medicine guideline of clinical investigations》About " new Chinese medicine treats the clinic of diarrhea
" the diarrhea common sympton scalar quantization table " of research guideline " design is formulated.Symptom overall score=stool and frequency meter
Score+difficult defecation degree of divide+having blood in stool is scored.
Stool and frequency：The basic forming of stool, 0 point of meter below daily defecation 3 times；Stool cannot shape, daily 3~
No. 41 point of meters；Loose watery stool, daily No. 5~10 2 points of meters；Stool such as water sample, it is above 10 times a day to count 3 points.
It has blood in stool：Without 0 point of meter of having blood in stool；It has blood in stool once in a while and counts 1 point；It often has blood in stool and counts 2 points；Whole blood just counts 3 points.
Difficult defecation degree：No difficult defecation meter 0 divides；Defecation is slightly difficult, and each defecation time, which is less than 30 minutes, counts 1 point；
Difficult defecation, each defecation time counted 2 points between 30 minutes~1 hour；Defecation exceptional hardship, each defecation time are more than 1
3 points of hour meter.
General curative effect comparison result is referring to table 1.The results show that test group total effective rate 95.2%, better than control group
(76.23%).In addition, after 1 course for the treatment of of treatment, the symptom general comment of control group is divided into (2.87 ± 1.05) point, and the disease of test group
Shape general comment is divided into (0.94 ± 0.33) point, compared with the control group with significant difference (P ＜ 0.01).
1 two groups of general curative effects of table compare
Claims (4)
1. a kind of application of pharmaceutical composition after treatment irradiation for cervical cancer is prepared in the external used medicine of chronic radioactive rectitis,
It is characterized in that：The pharmaceutical composition is prepared by traditional Chinese medicinal material raw materials, and by weight, the traditional Chinese medicinal material raw materials include：
7-15 parts of RADIX KADSURAE LONGIPEDUN LATAE, it is black lead a cow 11-20 parts, 10-25 parts of sophora flower, 6-10 parts of galanga galangal seed, 22-40 parts of chestnut shell, schizonepeta 6-10
Part, 9-20 parts of Herba Euphorbiae Humifusae, 6-10 parts of spina gleditsiae, 11-20 parts of fevervine.
2. application according to claim 1, it is characterised in that：By weight, the traditional Chinese medicinal material raw materials are by the southern five tastes
Sub- root 9-12 parts, it is black lead a cow 14-16 parts, 15-21 parts of sophora flower, 7-9 parts of galanga galangal seed, 28-32 parts of chestnut shell, 7-9 parts of schizonepeta, Herba Euphorbiae Humifusae
14-16 parts of 13-15 parts, 7-9 parts of spina gleditsiae and fevervine compositions.
3. application according to claim 1, it is characterised in that：By weight, the traditional Chinese medicinal material raw materials are by the southern five tastes
Sub- 10 parts of root, it is black lead a cow 15 parts, 18 parts of sophora flower, 8 parts of galanga galangal seed, 30 parts of chestnut shell, 8 parts of schizonepeta, 14 parts of Herba Euphorbiae Humifusae, 8 parts of spina gleditsiae
With 15 parts of compositions of fevervine.
4. application according to claim 1, which is characterized in that the external used medicine is enema fluid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510175736.7A CN104800721B (en) | 2015-04-14 | 2015-04-14 | A kind of pharmaceutical composition for treating factitial proctitis after irradiation for cervical cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510175736.7A CN104800721B (en) | 2015-04-14 | 2015-04-14 | A kind of pharmaceutical composition for treating factitial proctitis after irradiation for cervical cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104800721A CN104800721A (en) | 2015-07-29 |
| CN104800721B true CN104800721B (en) | 2018-06-19 |
Family
ID=53686200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510175736.7A Expired - Fee Related CN104800721B (en) | 2015-04-14 | 2015-04-14 | A kind of pharmaceutical composition for treating factitial proctitis after irradiation for cervical cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104800721B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103127317A (en) * | 2013-01-17 | 2013-06-05 | 田洪蕾 | Enema for treating radiation proctitis |
| CN103211883A (en) * | 2013-04-15 | 2013-07-24 | 李涌 | Chinese medicinal enema for treating cervical cancer chronic radiation proctitis |
-
2015
- 2015-04-14 CN CN201510175736.7A patent/CN104800721B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103127317A (en) * | 2013-01-17 | 2013-06-05 | 田洪蕾 | Enema for treating radiation proctitis |
| CN103211883A (en) * | 2013-04-15 | 2013-07-24 | 李涌 | Chinese medicinal enema for treating cervical cancer chronic radiation proctitis |
Non-Patent Citations (1)
| Title |
|---|
| 中医治疗放射性肠炎48例临床观察;郭峰 等;《甘肃医药》;19970815;第16卷(第3期);185 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104800721A (en) | 2015-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103356973B (en) | Antineoplastic traditional Chinese medicine | |
| CN101524464B (en) | Pure traditional Chinese medicine composition for treating female breast diseases and pure traditional Chinese medicine preparation prepared thereby | |
| CN103768398B (en) | Traditional Chinese medicine composition for treating advanced lung tumors | |
| CN103893738B (en) | A kind of suppression tumor growth Chinese medicine composition and preparation method thereof | |
| WO2016183783A1 (en) | Traditional chinese medicine for treating hyperplasia of mammary glands | |
| CN103505690A (en) | Medicament for treating chronic gastrointestinal tract diseases and preparation method of medicament | |
| CN103816483A (en) | Drug for treating middle-advanced stage esophagus cancer and preparation method thereof | |
| CN104800721B (en) | A kind of pharmaceutical composition for treating factitial proctitis after irradiation for cervical cancer | |
| CN110898182A (en) | Traditional Chinese medicine for treating liver-yang-hyperactivity and spleen-deficiency type ulcerative colitis and preparation system thereof | |
| CN104258260B (en) | A kind of saline cistanche alcohol extracting thing, preparation method and its usage | |
| CN106474230A (en) | Chinese medicine composition of preventing and treating Rana grylia torticollis disease and preparation method thereof | |
| CN104587214A (en) | Traditional Chinese medicine for preventing radiodermatitis caused by lung cancer radiotherapy | |
| CN114588240B (en) | Traditional Chinese medicine composition for treating colorectal cancer and preparation method and application thereof | |
| CN105663551A (en) | Traditional Chinese medicine preparation for patient suffering from pancreatic cancer to take after operation as well as preparation method | |
| CN106474229A (en) | A kind of protective agents of Rana grylia torticollis disease and preparation method thereof | |
| CN106511547A (en) | Medicine for preventing and treating frog disease in America and preparation method of medicine | |
| CN106361970A (en) | Traditional Chinese medicine for treating lung cancer | |
| CN105012789A (en) | Composition for treating cervical cancer and preparation method thereof | |
| CN105213597A (en) | Yao medicinal composition of a kind of Hepatoma therapy, gastric cancer, intestinal cancer and preparation method thereof | |
| CN105435031A (en) | Plaster for treating beriberi and preparation method thereof | |
| CN105055784A (en) | Traditional Chinese medicine for treating breast cancer | |
| CN117281876A (en) | Traditional Chinese medicine external treatment medicine bag | |
| CN103623354A (en) | Traditional Chinese medicinal preparation for treating retroperitoneal follicular dendritic cell sarcoma | |
| CN116570699A (en) | Traditional Chinese medicine composition for treating pulmonary nodules as well as preparation and application thereof | |
| CN103656570A (en) | Chinese medicine liquid for treating stomach tumor and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Song Xiufeng Inventor after: Zhuang Xunhui Inventor after: Li Weikai Inventor before: Song Xiufeng Inventor before: Liu Guangzhen Inventor before: Chen Jingjing Inventor before: Hua Hui Inventor before: Wang Guohua |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20180517 Address after: 266000 217 Liaoyang West Road, Shibei District, Qingdao, Shandong Applicant after: QINGDAO WOMEN AND CHILDREN'S HOSPITAL Address before: No. 16, Jiangsu Road, Southern District, Shandong, Qingdao, Shandong Applicant before: Affiliated Hospital of University Of Qingdao |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180619 Termination date: 20190414 |